
Opinion|Videos|January 20, 2025
A 70-Year-Old Man with Early Relapsed/Refractory Multiple Myeloma
Author(s)Amrita Krishnan, MD
The panelist discusses how the patient had triplet therapy 6 years ago, which was the standard for myeloma treatment at the time. Since then, the patient has had a biochemical relapse, renal insufficiency, and moderate anemia, so he needs therapy but not immediate therapy.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Please share your initial impressions of the patient case.
- A decision to switch therapy was made. What regimen are you most likely to recommend for this patient?
- How do you set a patient up for the best success in early-stage R/R MM?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5



















